Abstract
In this issue of Blood, Oliveri and colleagues and Magro and colleagues report pilot trials using imatinib for steroid refractory sclerotic cGVHD, showing response rates of 79% and 50%.
Original language | English (US) |
---|---|
Pages (from-to) | 498-499 |
Number of pages | 2 |
Journal | Blood |
Volume | 114 |
Issue number | 3 |
DOIs |
|
State | Published - 2009 |
Externally published | Yes |
ASJC Scopus subject areas
- Biochemistry
- Immunology
- Hematology
- Cell Biology